Skip to content
TrialScanner

NCT03752398

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

Phase 1CompletedXNCRLeadICLRCollaborator

Registry record

Lead sponsor
Xencor, Inc.
Conditions
Melanoma (Excluding Uveal Melanoma); Cervical Carcinoma; Pancreatic Carcinoma; Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative; Hepatocellular Carcinoma
Primary completion
Feb 15, 2024Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03752398 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03752398: A Study of XmAb®23104 in... | TrialScanner